Myocardial effects of VDR activators in renal failure

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the primary cause of mortality in chronic kidney disease (CKD) patients.
• Traditional risk factors do not fully account for the high CVD morbidity in CKD.
• The renin-angiotensin-aldosterone system (RAAS) plays a role in cardio-renal disease pathophysiology.

Purpose of the Study:

• To investigate the effects of vitamin D receptor activators (VDRAs) on cardiovascular complications in CKD.
• To evaluate paricalcitol's efficacy in ameliorating left ventricular hypertrophy (LVH) and cardiac fibrosis in a preclinical model.

Main Methods:

• Utilized a uremic rat model to study the effects of paricalcitol, a VDRA.
• Assessed paricalcitol's impact on vitamin D receptor (VDR) expression, myocardial proliferation (PCNA), oxidative stress, fibrosis, and arterial vessel thickness.

Main Results:

• Paricalcitol administration ameliorated LVH in uremic rats.
• Paricalcitol treatment decreased myocardial PCNA, oxidative stress, and fibrosis.
• The VDRA suppressed myocardial and perivascular fibrosis and myocardial arterial vessel thickness, likely via VDR upregulation.

Conclusions:

• Paricalcitol demonstrates potential to suppress the progression of cardiac complications in CKD.
• VDRAs may offer significant benefits for cardiac disease and outcomes in CKD patients.
• Further prospective randomized studies in CKD patients are warranted to confirm these findings.